Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples.
Ho-Pun-Cheung A, Bazin H, Boissière-Michot F, Mollevi C, Simony-Lafontaine J, Landas E, Bleuse JP, Chardès T, Prost JF, Pèlegrin A, Jacot W, Mathis G, Lopez-Crapez E. Ho-Pun-Cheung A, et al. Among authors: prost jf. Br J Cancer. 2020 Feb;122(3):397-404. doi: 10.1038/s41416-019-0670-8. Epub 2019 Dec 3. Br J Cancer. 2020. PMID: 31792349 Free PMC article.
Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3.
Le Clorennec C, Bazin H, Dubreuil O, Larbouret C, Ogier C, Lazrek Y, Garambois V, Poul MA, Mondon P, Barret JM, Mathis G, Prost JF, Pèlegrin A, Chardès T. Le Clorennec C, et al. Among authors: prost jf. Mol Cancer Ther. 2017 Jul;16(7):1312-1323. doi: 10.1158/1535-7163.MCT-16-0886. Epub 2017 May 15. Mol Cancer Ther. 2017. PMID: 28507002 Free article.
ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells.
Le Clorennec C, Lazrek Y, Dubreuil O, Sampaio C, Larbouret C, Lanotte R, Poul MA, Barret JM, Prost JF, Pèlegrin A, Chardès T. Le Clorennec C, et al. Among authors: prost jf. Cell Commun Signal. 2019 Aug 23;17(1):106. doi: 10.1186/s12964-019-0413-8. Cell Commun Signal. 2019. PMID: 31443721 Free PMC article.
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P, Fontayne A, Barret JM, Kersual N, Dubreuil O, Le Blay M, Pichard A, Jarlier M, Pugnière M, Chauvin M, Chardès T, Pouget JP, Deshayes E, Rossignol A, Abache T, de Romeuf C, Terrier A, Verhaeghe L, Gaucher C, Prost JF, Pèlegrin A, Navarro-Teulon I. Estupina P, et al. Among authors: prost jf. Oncotarget. 2017 Jun 6;8(23):37061-37079. doi: 10.18632/oncotarget.15715. Oncotarget. 2017. PMID: 28427157 Free PMC article.
The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages.
Bougherara H, Némati F, Nicolas A, Massonnet G, Pugnière M, Ngô C, Le Frère-Belda MA, Leary A, Alexandre J, Meseure D, Barret JM, Navarro-Teulon I, Pèlegrin A, Roman-Roman S, Prost JF, Donnadieu E, Decaudin D. Bougherara H, et al. Among authors: prost jf. Oncotarget. 2017 Oct 7;8(59):99950-99965. doi: 10.18632/oncotarget.21556. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29245952 Free PMC article.
Circulating CD14high CD16low intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression.
Prat M, Le Naour A, Coulson K, Lemée F, Leray H, Jacquemin G, Rahabi MC, Lemaitre L, Authier H, Ferron G, Barret JM, Martinez A, Ayyoub M, Delord JP, Gladieff L, Tabah-Fisch I, Prost JF, Couderc B, Coste A. Prat M, et al. Among authors: prost jf. J Immunother Cancer. 2020 Jun;8(1):e000472. doi: 10.1136/jitc-2019-000472. J Immunother Cancer. 2020. PMID: 32503947 Free PMC article.
The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer.
Barret JM, Nicolas A, Jarry A, Dubreuil O, Meseure D, Passat T, Perrial E, Deleine C, Champenois G, Gaillard S, Duchalais E, Ray-Coquard I, Lahmar M, Dumontet C, Bennouna J, Bossard C, Roman-Roman S, Prost JF. Barret JM, et al. Among authors: prost jf. Biology (Basel). 2021 Apr 7;10(4):305. doi: 10.3390/biology10040305. Biology (Basel). 2021. PMID: 33917111 Free PMC article.
Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.
de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, Jorieux S, Bihoreau N, Behrens CK, Béliard R, Vieillard V, Cazin B, Bourel D, Prost JF, Teillaud JL, Merle-Béral H. de Romeuf C, et al. Among authors: prost jf. Br J Haematol. 2008 Mar;140(6):635-43. doi: 10.1111/j.1365-2141.2007.06974.x. Br J Haematol. 2008. PMID: 18302712 Free article.
Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation.
Prat M, Salon M, Allain T, Dubreuil O, Noël G, Preisser L, Jean B, Cassard L, Lemée F, Tabah-Fish I, Pipy B, Jeannin P, Prost JF, Barret JM, Coste A. Prat M, et al. Among authors: prost jf. Cancers (Basel). 2021 Apr 13;13(8):1845. doi: 10.3390/cancers13081845. Cancers (Basel). 2021. PMID: 33924378 Free PMC article.
71 results